Table 1.
Sample Characteristics in Cases and Controls.
| Diagnostic Group | ||||
|---|---|---|---|---|
| Variable | Controls N = 404 |
Early MCI N = 294 |
Late MCI N = 539 |
AD N = 297 |
|
| ||||
| Age** (y), M±SD | 74.79±5.73 | 71.08±7.35 | 74.0±7.47 | 75.01±7.71 |
| Male* sex, n (%) | 203 (50.25) | 164 (55.78) | 329 (61.04) | 165 (55.56) |
| Education** (y), M±SD | 16.3±2.73 | 16.01±2.66 | 15.86±2.95 | 15.08±3.01 |
| Race, n (%) | ||||
| American Indian/Alaskan Native | 1 (0.25) | 1 (0.34) | 1 (0.18) | 0 (0) |
| Asian | 7 (1.73) | 4 (1.36) | 10 (1.86) | 6 (2.02) |
| Black or African American | 27 (6.68) | 6 (2.04) | 21 (3.90) | 12 (4.04) |
| Hawaiian or Other Pacific Islander | 0 (0) | 1 (0.34) | 1 (0.19) | 0 (0) |
| White | 367 (90.84) | 273 (92.86) | 505 (93.69) | 275 (92.59) |
| More than one race | 2 (0.50) | 6 (2.04) | 1 (0.19) | 4 (1.35) |
| Unknown | 0 (0) | 3 (1.02) | 0 (0) | 0 (0) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 13 (3.22) | 13 (4.42) | 15 (2.78) | 8 (2.69) |
| Not Hispanic or Latino | 389 (96.29) | 280 (95.24) | 521 (96.66) | 287 (96.63) |
| Total Cholesterol (mg/dL), M±SD | 191.9±38.78 | 193.4±39.80 | 196.3±40.16 | 197±41.39 |
| CM Use**, n (%) | 84 (20.79) | 57 (19.39) | 152 (28.20) | 105 (35.35) |
| APOE Genotype**, n (%) | ||||
| APOE2+ (ε2/2, ε2/3) | 54 (13.37) | 23 (7.82) | 28 (5.19) | 10 (3.37) |
| APOE3 (ε3/3) | 241 (59.65) | 149 (50.68) | 224 (41.56) | 85 (28.62) |
| APOE4+ (ε3/4, ε4/4) | 109 (26.98) | 122 (41.50) | 287 (53.25) | 202 (68.01) |
| Body Mass Index**, M±SD | 26.96±4.39 | 27.99±5.15 | 26.49±4.29 | 25.67±4.26 |
| Smoking, n (%) | 154 (38.12) | 116 (39.46) | 212 (39.33) | 108 (36.36) |
| CVD, n (%) | 271 (67.08) | 198 (67.35) | 373 (69.20) | 206 (69.36) |
| Alcohol Abuse, n (%) | 14 (3.46) | 14 (4.76) | 19 (3.53) | 18 (6.06) |
MCI, mild cognitive impairment; AD, Alzheimer’s disease; M, mean; SD, standard deviation; CM, cholesterol-lowering medication; CVD, cardiovascular disease.
*
p < 0.05
**
p < 0.001